Table 2. Referral rates, CIN2+/CIN3+ detection rates and positive predictive values by trial arm in round 1 of screening.
| HPV arm (95%CI) | Control arm (95%CI) | |
| Referral rates per 1000 tested | ||
| Round 1 baseline colposcopy | 28.9 (26.0, 31.9) | 32.1 (27.6, 36.5) |
| Recommended for follow-up | 52.0 (48.1, 55.9) | 6.9 (4.8, 8.9) |
| Round 1 follow-up colposcopy | 544.7 (494.5, 594.9) | 162.2 (40.1,284.2) |
| Round 1 overall colposcopy | 57.2 (52.8, 61.7) | 33.2 (28.7, 37.7) |
| CIN2+/CIN3+ detection rates per 1000 tested | ||
| Round 1 baseline CIN2+ | 9.2 (7.4, 10.9) | 11.0 (8.3.13.7) |
| Round 1 baseline CIN3+ | 4.8 (3.6, 6.1) | 5.0 (3.1, 6.8) |
| Round 1 subsequent CIN2+ | 244.1 (168.8, 319.4) | 0.0 (0.0, 489.9) |
| Round 1 subsequent CIN3+ | 110.2 (55.3, 165.1) | 0.0 (0.0, 489.9) |
| Round 1 overall CIN2+ | 16.1 (13.2, 18.9) | 11.0 (8.3, 13.7) |
| Round 1 overall CIN3+ | 8.0 (5.9, 10.0) | 5.0 (3.1, 6.8) |
| Positive predictive value | ||
| Baseline CIN2+ | 31.6% (26.6, 36.6) | 34.3% (27.3, 41.2) |
| Baseline CIN3+ | 16.7% (12.7, 20.7) | 15.5% (10.2, 20.8) |
| Subsequent CIN2+ | 24.4% (16.9, 31.9) | 0% (0.0, 49.0) |
| Subsequent CIN3+ | 11.0% (5.5, 16.5) | 0% (0.0, 49.0) |
| Overall CIN2+ | 28.1% (23.6, 32.6) | 33.1% (26.3, 39.9) |
| Overall CIN3+ | 13.9 (10.5, 17.3) | 15.0% (9.8, 20.1) |
Abbreviations: CI=confidence interval; CIN=cervical intraepithelial neoplasia; HPV=human papillomavirus; PPV=positive predictive value.